

Bernard Zinman Cm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2414078/publications.pdf>

Version: 2024-02-01

263
papers

52,610
citations

6840

81
h-index

1518

224
g-index

268
all docs

268
docs citations

268
times ranked

28629
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes, Obesity and Metabolism, 2022, 24, 135-141.	2.2	29
2	The ongoing evolution of basal insulin therapy over 100 years and its promise for the future. Diabetes, Obesity and Metabolism, 2022, 24, 17-26.	2.2	12
3	Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2022, 45, 357-364.	4.3	24
4	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care, 2022, 45, 585-593.	4.3	1
5	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine, 2022, 43, 101240.	3.2	6
6	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	1.4	5
7	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022, 145, 575-585.	1.6	88
8	Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12268.	1.8	39
9	Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3003-e3007.	1.8	12
10	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, Obesity and Metabolism, 2022, 24, 1061-1071.	2.2	15
11	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. Diabetes Research and Clinical Practice, 2022, 186, 109837.	1.1	5
12	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
13	Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
14	Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?. Diabetes Care, 2022, 45, 1532-1539.	4.3	10
15	Characterization and implications of the initial estimated glomerular filtration rate (eGFR) upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99, 750-762.	2.6	111
16	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, Obesity and Metabolism, 2021, 23, 569-580.	2.2	18
17	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2021, 99, 999-1009.	2.6	93
18	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 226-236.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	2.2	37
20	Impact of polyvascular disease with and without coexistent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of <sc>EMPAâ€REG OUTCOME</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1173-1181.	2.2	11
21	Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. <i>Diabetologia</i> , 2021, 64, 1235-1245.	2.9	20
22	Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPAâ€REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020053.	1.6	9
23	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
24	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <sc>CREDENCE</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	2.2	6
25	Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. <i>Cell Metabolism</i> , 2021, 33, 740-747.	7.2	27
26	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the <sc>EMPAâ€REG OUTCOME</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1085-1093.	2.9	23
27	Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (<sc>RESET Main</sc>): A 2-year randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1926-1935.	2.2	8
28	Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort. <i>Diabetes Care</i> , 2021, 44, 1682-1691.	4.3	16
29	Time to cardiovascular benefits of empagliflozin: a <i>post hoc</i> observation from the EMPAâ€REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 2603-2607.	1.4	16
30	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <sc>EMPAâ€REG OUTCOME</sc> trial with a focus on Asia. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1886-1891.	2.2	18
31	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1164-1173.	2.3	51
32	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 568-577.	1.9	8
33	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <sc>EMPAâ€REG OUTCOME</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2775-2784.	2.2	12
34	The discovery of insulin in Toronto: beginning a 100-year journey of research and clinical achievement. <i>Diabetologia</i> , 2021, 64, 947-953.	2.9	25
35	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPAâ€REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	1.4	46
36	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2020, 41, 209-217.	1.0	28

#	ARTICLE	IF	CITATIONS
37	The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β -cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e285-e294.	1.8	9
38	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , 2020, 11, 53-70.	1.2	18
39	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c \leq 7%. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
40	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2020, 141, 704-707.	1.6	225
41	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020, 22, 126-135.	2.9	67
42	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 631-639.	2.2	58
43	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2020, 43, 3007-3015.	4.3	45
44	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. <i>ESC Heart Failure</i> , 2020, 7, 3401-3407.	1.4	14
45	Effects of Canagliflozin in Patients with Baseline eGFR \leq 30 ml/min per 1.73 m ² . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
46	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 200.	2.7	13
47	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 949-959.	5.5	41
48	Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2335-2347.	2.2	22
49	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2487-2492.	2.2	31
50	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , 2020, 38, 1829-1840.	0.3	15
51	Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 834-844.	5.5	103
52	Short-term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016976.	1.6	39
53	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097525.	0.9	9
54	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412097093.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. <i>Alzheimer's and Dementia</i> , 2020, 16, e042909.	0.4	13
56	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.	4.3	92
57	Empagliflozin for Patients With Presumed Resistant Hypertension: A <i>Post Hoc</i> Analysis of the EMPA-REG OUTCOME Trial. <i>American Journal of Hypertension</i> , 2020, 33, 1092-1101.	1.0	23
58	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
59	LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE "EGFR DIP"™ IN EMPA-REG OUTCOME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	1
60	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	1.8	22
61	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 895-897.	0.4	22
62	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 644-646.	1.2	18
63	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1151-1156.	2.2	8
64	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> 2020;69:291-299. <i>Diabetes</i> , 2020, 69, e7-e8.	0.3	3
65	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. <i>Metabolism Open</i> , 2020, 7, 100039.	1.4	14
66	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2193-2198.	2.2	11
67	Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1207-1214.	2.2	29
68	The authors reply. <i>Kidney International</i> , 2020, 97, 213-214.	2.6	0
69	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1141-1150.	2.2	20
70	Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 1157-1163.	4.3	38
71	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	4.3	44
72	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. <i>Diabetes</i> , 2020, 69, 131-LB.	0.3	1

#	ARTICLE	IF	CITATIONS
73	Serum Ferritin and Glucose Homeostasis in Women With Recent Gestational Diabetes. Canadian Journal of Diabetes, 2019, 43, 567-572.	0.4	5
74	The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort. Lipids, 2019, 54, 617-627.	0.7	4
75	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) â€“ A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
76	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	2.2	8
77	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
78	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. American Journal of Kidney Diseases, 2019, 74, 713-715.	2.1	33
79	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovascular Diabetology, 2019, 18, 156.	2.7	17
80	Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction. Journal of the American Heart Association, 2019, 8, e014231.	1.6	6
81	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371
82	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metabolism, 2019, 30, 609-613.	7.2	69
83	Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes Care, 2019, 42, 1930-1938.	4.3	52
84	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019, 42, 2262-2271.	4.3	146
85	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1155.	3.8	423
86	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. Age and Ageing, 2019, 48, 859-866.	0.7	79
87	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e53-e55.	4.3	27
88	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e42-e44.	4.3	25
89	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 854-861.	2.2	37
90	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circulation: Heart Failure, 2019, 12, e005875.	1.6	38

#	ARTICLE	IF	CITATIONS
91	Intermittent Intensive Insulin Therapy for Type 2 Diabetes: Effects on Hypoglycemia, Weight Gain, and Quality of Life Over 2 Years. <i>Endocrine Practice</i> , 2019, 25, 899-907.	1.1	3
92	Sodium-glucose cotransporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2192-2202.	2.2	69
93	Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 577-581.	0.9	17
94	Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019, 96, 489-504.	2.6	77
95	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1745-1751.	2.2	22
96	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1625-1633.	2.2	18
97	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019, 139, 1458-1460.	1.6	49
98	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2780-2782.	1.2	30
99	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 356-367.	5.5	210
100	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	13.9	3,760
101	Short-term cost utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1706-1714.	2.2	3
102	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1437-1444.	2.2	13
103	Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000825.	1.2	14
104	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.	1.6	126
105	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.	3.8	830
106	HbA1c, Insulin Resistance, and Î²-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy. <i>Diabetes Care</i> , 2019, 42, e1-e3.	4.3	19
107	Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 622-630.	2.2	15
108	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019, 139, 1384-1395.	1.6	205

#	ARTICLE	IF	CITATIONS
109	Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. <i>Molecular Metabolism</i> , 2019, 20, 63-78.	3.0	40
110	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME [®] trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	1.0	199
111	Two-year trial of intermittent insulin therapy vs metformin for the preservation of β -cell function after initial short-term intensive insulin induction in early type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1399-1407.	2.2	20
112	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
113	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 105-113.	5.5	451
114	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINA [®]): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018, 17, 39.	2.7	70
115	Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME [®] . <i>Diabetologia</i> , 2018, 61, 1522-1527.	2.9	49
116	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , 2018, 61, 58-65.	2.9	124
117	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , 2018, 61, 48-57.	2.9	126
118	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
119	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	4.3	534
120	Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E287-E295.	1.8	13
121	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 405-407.	1.6	131
122	Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, e4-e5.	4.3	143
123	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 1599-1601.	1.6	28
124	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018, 41, 2560-2569.	4.3	239
125	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018, 138, 2884-2894.	1.6	82
126	Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease". <i>Circulation</i> , 2018, 138, 850-851.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018, 9, 2383-2392.	1.2	23
128	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , 2018, 138, 1904-1907.	1.6	117
129	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2755-2769.	3.0	148
130	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. <i>Diabetes Care</i> , 2018, 41, 1121-1124.	4.3	43
131	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. <i>Diabetologia</i> , 2018, 61, 1712-1723.	2.9	88
132	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.	1.6	80
133	SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i487-i487.	0.4	0
134	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. <i>Physiology</i> , 2018, 33, 197-210.	1.6	3
135	Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. <i>Diabetologia</i> , 2018, 61, 2155-2163.	2.9	133
136	Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes. <i>Journal of Lipid Research</i> , 2018, 59, 1751-1762.	2.0	7
137	Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. <i>BMC Neurology</i> , 2018, 18, 7.	0.8	26
138	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
139	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. <i>Diabetes Care</i> , 2018, 41, 1783-1791.	4.3	82
140	Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 744-748.	2.2	13
141	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2017, 40, 777-783.	4.3	141
142	Novel Diabetes Drugs and the Cardiovascular Specialist. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2646-2656.	1.2	75
143	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	13.9	480
144	Asymmetric dimethylarginine and arginine metabolites in women with and without a history of gestational diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 964-970.	1.2	5

#	ARTICLE	IF	CITATIONS
145	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
146	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
147	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , 2017, 40, 793-799.	4.3	18
148	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , 2017, 40, e165-e166.	4.3	2
149	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 839-848.	13.9	903
150	Bladder cancer in the EMPA-REG OUTCOME trial. <i>Diabetologia</i> , 2017, 60, 2534-2535.	2.9	24
151	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
152	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017, 40, 1302-1313.	4.3	11
153	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000461.	1.2	9
154	Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes Care</i> , 2017, 40, 1756-1762.	4.3	77
155	Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk" • <i>Stroke</i> , 2017, 48, e256-e257.	1.0	0
156	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 610-621.	5.5	301
157	Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. <i>Canadian Journal of Diabetes</i> , 2017, 41, 6-9.	0.4	12
158	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	1.4	194
159	Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000270.	1.2	47
160	Traditional foods and 25(OH)D concentrations in a subarctic First Nations community. <i>International Journal of Circumpolar Health</i> , 2016, 75, 31956.	0.5	8
161	Evaluation of Circulating Determinants of Beta-Cell Function in Women With and Without Gestational Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2683-2691.	1.8	44
162	Maternal Serum Prolactin and Prediction of Postpartum β -Cell Function and Risk of Prediabetes/Diabetes. <i>Diabetes Care</i> , 2016, 39, 1250-1258.	4.3	49

#	ARTICLE	IF	CITATIONS
163	LEADER-4. Journal of Hypertension, 2016, 34, 1140-1150.	0.3	13
164	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Journal, 2016, 179, 175-183.	1.2	58
165	Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. Canadian Journal of Diabetes, 2016, 40, 379-381.	0.4	1
166	Steno-2 " a small study with a big heart. Nature Reviews Endocrinology, 2016, 12, 692-694.	4.3	6
167	Longitudinal Associations of Phospholipid and Cholesteryl Ester Fatty Acids With Disorders Underlying Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2536-2544.	1.8	11
168	Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 2016, 39, 1702-1710.	4.3	200
169	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1969-1977.	2.2	93
170	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 311-322.	13.9	5,070
171	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 323-334.	13.9	2,809
172	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCCEL) trial. American Heart Journal, 2016, 174, 103-110.	1.2	82
173	The Relationship Between Parathyroid Hormone and 25-Hydroxyvitamin D During and After Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1729-1736.	1.8	16
174	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. Canadian Journal of Diabetes, 2016, 40, 50-57.	0.4	27
175	Treatment of Type 1 Diabetes Mellitus in Adults. , 2016, , 770-787.e4.		0
176	Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum. Diabetologia, 2015, 58, 1354-1362.	2.9	16
177	Associations of circulating 25(OH)D with cardiometabolic disorders underlying type 2 diabetes mellitus in an Aboriginal Canadian community. Diabetes Research and Clinical Practice, 2015, 109, 440-449.	1.1	12
178	Erythropoietin and glucose homeostasis in women at varying degrees of future diabetic risk. Journal of Diabetes and Its Complications, 2015, 29, 26-31.	1.2	3
179	Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA - Journal of the American Medical Association, 2015, 313, 45.	3.8	369
180	Fetal Sex and Maternal Risk of Gestational Diabetes Mellitus: The Impact of Having a Boy. Diabetes Care, 2015, 38, 844-851.	4.3	112

#	ARTICLE	IF	CITATIONS
181	Response to Comment on Retnakaran et al. Liraglutide and the Preservation of Pancreatic β -Cell Function in Early Type 2 Diabetes: The LIBRA Trial. <i>Diabetes Care</i> 2014;37:3270-3278. <i>Diabetes Care</i> , 2015, 38, e26-e26.	4.3	0
182	Design and baseline characteristics of the CARDiovascular Outcome Trial of LINagliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA [®]). <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 164-174.	0.9	197
183	Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial. <i>Advances in Therapy</i> , 2015, 32, 201-215.	1.3	15
184	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015, 38, 793-800.	4.3	104
185	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 90-100.	0.9	333
186	Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2987-2995.	1.8	15
187	Sex of the baby and risk of gestational diabetes mellitus in the mother: a systematic review and meta-analysis. <i>Diabetologia</i> , 2015, 58, 2469-2475.	2.9	62
188	The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3702-3709.	1.8	49
189	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 2117-2128.	13.9	8,841
190	Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 132-139.	4.3	137
191	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0141085.	1.1	28
192	The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study: 30th Anniversary Presentations. <i>Diabetes Care</i> , 2014, 37, 8-8.	4.3	24
193	Vitamin D and Parathyroid Hormone Status in Pregnancy: Effect on Insulin Sensitivity, β -cell Function, and Gestational Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4506-4513.	1.8	44
194	Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. <i>Diabetes Care</i> 2014;37:1076-1082. <i>Diabetes Care</i> , 2014, 37, e225-e225.	4.3	0
195	Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. <i>Diabetes Care</i> 2014;37:1076-1082. <i>Diabetes Care</i> , 2014, 37, e209-e209.	4.3	1
196	Oscar B. Crofford: Clinician, Scientist, Educator, Advocate for People With Diabetes, and Godfather of Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2014, 37, 3139-3142.	4.3	2
197	Cardiometabolic Implications of Postpartum Weight Changes in the First Year After Delivery. <i>Diabetes Care</i> , 2014, 37, 1998-2006.	4.3	73
198	Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. <i>Diabetes Care</i> , 2014, 37, 1480-1483.	4.3	211

#	ARTICLE	IF	CITATIONS
199	Each Degree of Glucose Intolerance in Pregnancy Predicts Distinct Trajectories of β -Cell Function, Insulin Sensitivity, and Glycemia in the First 3 Years Postpartum. <i>Diabetes Care</i> , 2014, 37, 3262-3269.	4.3	89
200	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME [®] , ϕ). <i>Cardiovascular Diabetology</i> , 2014, 13, 102.	2.7	198
201	Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. <i>Diabetes Care</i> , 2014, 37, 1076-1082.	4.3	27
202	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 810-818.	3.0	40
203	Progress in reducing vascular complications of diabetes. <i>Nature Reviews Endocrinology</i> , 2014, 10, 451-453.	4.3	5
204	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2342-2350.	3.0	76
205	Liraglutide and the Preservation of Pancreatic β -Cell Function in Early Type 2 Diabetes: The LIBRA Trial. <i>Diabetes Care</i> , 2014, 37, 3270-3278.	4.3	115
206	Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies. <i>Canadian Journal of Diabetes</i> , 2014, 38, 364-371.	0.4	35
207	Prospective Associations of Vitamin D Status With β -Cell Function, Insulin Sensitivity, and Glycemia: The Impact of Parathyroid Hormone Status. <i>Diabetes</i> , 2014, 63, 3868-3879.	0.3	49
208	Glycemic Variability in Patients With Early Type 2 Diabetes: The Impact of Improvement in β -Cell Function. <i>Diabetes Care</i> , 2014, 37, 1116-1123.	4.3	54
209	Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. <i>Lancet</i> , The, 2014, 384, 2228-2234.	6.3	336
210	Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: Reproducibility and implications for glucose homeostasis in individuals with and without diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 105, 88-95.	1.1	45
211	Delivery by Caesarean Section and Infant Cardiometabolic Status at One Year of Age. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 864-869.	0.3	4
212	Newer insulin analogs: advances in basal insulin replacement. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 6-10.	2.2	32
213	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013, 166, 823-830.e5.	1.2	182
214	Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2013, 1, 28-34.	5.5	183
215	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 289-301.	0.9	132
216	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naïve patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2013, 1, 123-131.	5.5	37

#	ARTICLE	IF	CITATIONS
217	Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions. <i>Diabetes</i> , 2013, 62, 3976-3986.	0.3	215
218	Determinants of reversibility of β -cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E1398-E1407.	1.8	46
219	Clinical inertia—a barrier to effective management of T2DM. <i>Nature Reviews Endocrinology</i> , 2013, 9, 635-636.	4.3	18
220	Fasting Capillary Glucose as a Screening Test for Ruling Out Gestational Diabetes Mellitus. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 515-522.	0.3	11
221	Predictors and Clinical Implications of a False Negative Glucose Challenge Test in Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 889-898.	0.3	6
222	Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2464-2471.	4.3	305
223	Insulins: Past, Present, and Future. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 1-24.	1.2	36
224	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2011, 365, 2366-2376.	13.9	507
225	Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?. <i>American Journal of Medicine</i> , 2011, 124, S19-S34.	0.6	65
226	Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. <i>Lancet</i> , The, 2011, 377, 924-931.	6.3	122
227	Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria_{title}>An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort</sub>><alt-title>Microalbuminuria Outcomes in Type 1 Diabetes</alt-title>>. <i>Archives of Internal Medicine</i> , 2011, 171, 412.	4.3	298
228	Changes Over Time in Glycemic Control, Insulin Sensitivity, and β -Cell Function in Response to Low-Dose Metformin and Thiazolidinedione Combination Therapy in Patients With Impaired Glucose Tolerance. <i>Diabetes Care</i> , 2011, 34, 1601-1604.	4.3	25
229	Prospective Associations of Vitamin D With β -Cell Function and Glycemia. <i>Diabetes</i> , 2011, 60, 2947-2953.	0.3	124
230	Effect of Rosiglitazone and Ramipril on β -Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: The DREAM trial. <i>Diabetes Care</i> , 2010, 33, 608-613.	4.3	50
231	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2010, 33, 1536-1543.	4.3	257
232	Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 134-142.	1.8	164
233	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. <i>Lancet</i> , The, 2010, 376, 103-111.	6.3	216
234	Association of Hematological Parameters with Insulin Resistance and β -Cell Dysfunction in Nondiabetic Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3824-3832.	1.8	69

#	ARTICLE	IF	CITATIONS
235	The clinical challenges of managing type 2 diabetes and the potential of GLP-1 based therapies. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 1-3.	2.2	1
236	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). <i>Diabetes Care</i> , 2009, 32, 1224-1230.	4.3	768
237	Hyperbolic Relationship Between Insulin Secretion and Sensitivity on Oral Glucose Tolerance Test. <i>Obesity</i> , 2008, 16, 1901-1907.	1.5	297
238	Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited. <i>Diabetes</i> , 2008, 57, 995-1001.	0.3	432
239	Rosiglitazone-Associated Fractures in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 845-851.	4.3	498
240	Does an intensive multifactorial intervention reduce mortality in type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 434-435.	2.9	0
241	The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2007, 146, 477.	2.0	387
242	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 2427-2443.	13.9	2,714
243	Efficacy and Safety of Inhaled Insulin Therapy. <i>Annals of Internal Medicine</i> , 2006, 144, 533.	2.0	2
244	Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2005, 353, 2643-2653.	13.9	4,433
245	Clinical Inertia in Response to Inadequate Glycemic Control: Do specialists differ from primary care physicians?. <i>Diabetes Care</i> , 2005, 28, 600-606.	4.3	348
246	Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe. <i>Diabetes</i> , 2004, 53, 3193-3200.	0.3	154
247	Insulins today and beyond. <i>Lancet, The</i> , 2001, 358, 739-746.	6.3	353
248	PPAR γ agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 34-43.	2.2	31
249	The pharmacokinetics of insulin analogues and pumps. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, S3-S4.	0.2	2
250	PPAR γ agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3 Suppl 1, 34-43.	2.2	0
251	Overweight among children and adolescents in a Native Canadian community: prevalence and associated factors. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 693-700.	2.2	229
252	Common and Rare <i>ABCA1</i> Variants Affecting Plasma HDL Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1983-1989.	1.1	117

#	ARTICLE	IF	CITATIONS
253	Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers. <i>Journal of Human Genetics</i> , 1999, 44, 10-14.	1.1	53
254	The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree. <i>Journal of Human Genetics</i> , 1999, 44, 225-229.	1.1	11
255	âˆ6A Promoter variant of angiotensinogen and blood pressure variation in Canadian Oji-Cree. <i>Journal of Human Genetics</i> , 1998, 43, 37-41.	1.1	23
256	Genetic variation in paraoxonaseâ€2 is associated with variation in plasma lipoproteins in Canadian Ojiâ€Cree. <i>Clinical Genetics</i> , 1998, 54, 394-399.	1.0	23
257	Paraoxonase-2 Gene (PON2) G148 Variant Associated with Elevated Fasting Plasma Glucose in Noninsulin-Dependent Diabetes Mellitus1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3373-3377.	1.8	75
258	Angiotensinogen Gene Variation Associated With Variation in Blood Pressure in Aboriginal Canadians. <i>Hypertension</i> , 1997, 29, 1073-1077.	1.3	34
259	Body Image Concepts Differ by Age and Sex in an Ojibway-Cree Community in Canada. <i>Journal of Nutrition</i> , 1996, 126, 2990-3000.	1.3	58
260	Effect of Hyperglycaemia on Arterial Pressure, Plasma Renin Activity and Renal Function in Early Diabetes. <i>Clinical Science</i> , 1996, 90, 189-195.	1.8	97
261	The Physiologic Replacement of Insulin. <i>New England Journal of Medicine</i> , 1989, 321, 363-370.	13.9	130
262	The Role of Insulin in the Metabolic Response to Exercise in Diabetic Man. <i>Diabetes</i> , 1979, 28, 76-81.	0.3	48
263	Glucoregulation During Moderate Exercise in Insulin Treated Diabetics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1977, 45, 641-652.	1.8	174